[go: up one dir, main page]

MX2009003400A - Compuestos antidiabeticos. - Google Patents

Compuestos antidiabeticos.

Info

Publication number
MX2009003400A
MX2009003400A MX2009003400A MX2009003400A MX2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A MX 2009003400 A MX2009003400 A MX 2009003400A
Authority
MX
Mexico
Prior art keywords
peptidomimetics
antidiabetic compounds
glp
sub
found
Prior art date
Application number
MX2009003400A
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Mukul R Jain
Rajesh H Bahekar
Pankaj Ramanbhai Patel
Kaushik M Banerjee
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MX2009003400A publication Critical patent/MX2009003400A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona nuevos peptidomiméticos de fórmula (I), que principalmente actúan como secretagogos de insulina dependiente de glucosa. Por otra parte, se encontró que estos peptidomiméticos muestran actividad antagonista respecto al receptor del glucagón y también actividad agonista respecto al receptor del GLP-1. A-Z1-Z2-Z3-Z4-Z5-Z6-Z7-Z8-Z9-Z10-Z11-B (I).
MX2009003400A 2006-10-03 2007-09-28 Compuestos antidiabeticos. MX2009003400A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1632MU2006 2006-10-03
IN1965MU2006 2006-11-30
IN423MU2007 2007-03-06
PCT/IN2007/000457 WO2008062457A2 (en) 2006-10-03 2007-09-28 Antidiabetic compounds

Publications (1)

Publication Number Publication Date
MX2009003400A true MX2009003400A (es) 2009-04-28

Family

ID=39430173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003400A MX2009003400A (es) 2006-10-03 2007-09-28 Compuestos antidiabeticos.

Country Status (9)

Country Link
US (1) US8841413B2 (es)
EP (1) EP2084182B1 (es)
JP (1) JP5247708B2 (es)
AU (1) AU2007323035B2 (es)
CA (1) CA2665033C (es)
DK (1) DK2084182T3 (es)
MX (1) MX2009003400A (es)
NZ (1) NZ576023A (es)
WO (1) WO2008062457A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2707448C (en) * 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8685895B2 (en) 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
IN2015DN03795A (es) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
CN109311934B (zh) * 2016-04-01 2022-04-29 华盛顿大学 能够形成具有模块化氢键网络介导特异性的同型寡聚体的多肽及其设计
CN118924717A (zh) 2017-09-20 2024-11-12 硫创治疗公司 用于治疗半胱胺敏感性病症的方法
WO2020098657A1 (zh) * 2018-11-12 2020-05-22 天津药物研究院有限公司 具有双重受体激动作用的胰高血糖素衍生肽及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005664A1 (en) * 2000-04-25 2004-01-08 Millennium Pharmaceuticals, Inc. Novel 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 molecules and uses therefor
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US7238670B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
KR20080021636A (ko) * 2005-05-05 2008-03-07 카딜라 핼쓰캐어 리미티드 Ｇｌｐ-1 아고니스트인 신규 화합물

Also Published As

Publication number Publication date
JP5247708B2 (ja) 2013-07-24
AU2007323035B2 (en) 2011-11-24
CA2665033A1 (en) 2008-05-29
DK2084182T3 (da) 2013-11-04
NZ576023A (en) 2012-06-29
US8841413B2 (en) 2014-09-23
WO2008062457A2 (en) 2008-05-29
EP2084182B1 (en) 2013-08-28
EP2084182A2 (en) 2009-08-05
WO2008062457A3 (en) 2008-10-02
JP2010505820A (ja) 2010-02-25
US20130225488A1 (en) 2013-08-29
AU2007323035A1 (en) 2008-05-29
WO2008062457A8 (en) 2008-08-07
CA2665033C (en) 2013-10-01

Similar Documents

Publication Publication Date Title
MX2009003400A (es) Compuestos antidiabeticos.
CA2707448C (en) Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
MY154798A (en) Fused cyclic compounds
MX2011011763A (es) Composiciones plaguicidas.
TW200626559A (en) Anilino-pyrimidine analogs
WO2007109456A3 (en) Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists
GEP20125506B (en) Glucagon receptor antagonist compounds, compositions containing such compounds and use
WO2009043889A3 (en) Oxadiazole derivatives
WO2012015975A3 (en) Glp-1 receptor agonist compounds having stabilized regions
MY153283A (en) A use of sulfonanilides as herbicide
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
MX2009010552A (es) Antagonistas de receptor de opioide periferico y usos de los mismos.
WO2007146867A3 (en) Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity
MX2011006334A (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
IL189996A0 (en) Stabilized glp-1 analogs
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MX2010006787A (es) Análogos halogenados de agentes anti-fibroticos.
PH12012502033A1 (en) Pesticidal composition and its use
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
TW200740814A (en) Compounds
TN2009000536A1 (en) Novel herbicides
MX2010005650A (es) Derivados de diazabicicloalcano substituidos con biarilo.
MX2009012734A (es) Derivados de azaciclilbenzamida como antagonistas de histamina-3.
WO2008107771A3 (en) 2',3'-di-o-acyl-5-fluoronucleosides

Legal Events

Date Code Title Description
FG Grant or registration